Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.
Superinfection by a second human immunodeficiency virus type 1 (HIV-1) strain indicates that gaps in protective immunity occur during natural infection. To define the role of HIV-1-specific neutralizing antibodies (NAbs) in this setting, we examined NAb responses in 6 women who became superinfected between approximately 1 to 5 years following initial infection compared to 18 women with similar risk factors who did not. Although superinfected individuals had less NAb breadth than matched controls at approximately 1 year postinfection, no significant differences in the breadth or potency of NAb responses were observed just prior to the second infection. In fact, four of the six subjects had relatively broad and potent NAb responses prior to infection by the second strain. To more specifically examine the specificity of the NAbs against the superinfecting virus, these variants were cloned from five of the six individuals. The superinfecting variants did not appear to be inherently neutralization resistant, as measured against a pool of plasma from unrelated HIV-infected individuals. Moreover, the superinfected individuals were able to mount autologous NAb responses to these variants following reinfection. In addition, most superinfected individuals had NAbs that could neutralize their second viral strains prior to their reinfection, suggesting that the level of NAbs elicited during natural infection was not sufficient to block infection. These data indicate that preventing infection by vaccination will likely require broader and more potent NAb responses than those found in HIV-1-infected individuals.
Blish
Catherine A
CA
Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Dogan
Ozge C
OC
Derby
Nina R
NR
Nguyen
Minh-An
MA
Chohan
Bhavna
B
Richardson
Barbra A
BA
Overbaugh
Julie
J
D005260:Female; D015483:HIV Antibodies / Q000276:immunology* / Q000494:pharmacology*; D015658:HIV Infections / Q000097:blood / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D009154:Mutation / Q000235:genetics; D010802:Phylogeny; D015163:Superinfection / Q000276:immunology*; D013997:Time Factors; D054299:env Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000378:metabolism
D015483:HIV Antibodies; D054299:env Gene Products, Human Immunodeficiency Virus